Resultados de procura - Keyvan Tadjalli-Mehr

  • Mostrando 1 - 2 Resultados de 2
Limitar resultados
  1. 1
    RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial

    RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial por Fatma Doener, Henoch S. Hong, Ingo Meyer, Keyvan Tadjalli-Mehr, Angelika Daehling, Regina Heidenreich, Sven D. Koch, Mariola Fotin‐Mleczek, Ulrike Gnad-Vogt

    Publicado 2019
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:
  2. 2
    TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial

    TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial por Aung Naing, Meredith McKean, Anthony W. Tolcher, Anja Victor, Ping Hu, Wei Gao, Marco Antonio Ferraz Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel J. Holland, Emilia Richter, Keyvan Tadjalli-Mehr, Lillian L. Siu

    Publicado 2025
    Ligazón do recurso
    Artigo
    Engadir a favoritos
    Gardado en:

Ferramentas de procura: